BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16913696)

  • 1. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques.
    Ekins S; Balakin KV; Savchuk N; Ivanenkov Y
    J Med Chem; 2006 Aug; 49(17):5059-71. PubMed ID: 16913696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability.
    Leong MK
    Chem Res Toxicol; 2007 Feb; 20(2):217-26. PubMed ID: 17261034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classification models for HERG inhibitors by counter-propagation neural networks.
    Thai KM; Ecker GF
    Chem Biol Drug Des; 2008 Oct; 72(4):279-89. PubMed ID: 18844674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining cluster analysis, feature selection and multiple support vector machine models for the identification of human ether-a-go-go related gene channel blocking compounds.
    Nisius B; Göller AH; Bajorath J
    Chem Biol Drug Des; 2009 Jan; 73(1):17-25. PubMed ID: 19152631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hERG classification model based on a combination of support vector machine method and GRIND descriptors.
    Li Q; Jørgensen FS; Oprea T; Brunak S; Taboureau O
    Mol Pharm; 2008; 5(1):117-27. PubMed ID: 18197627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
    Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
    Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A binary QSAR model for classification of hERG potassium channel blockers.
    Thai KM; Ecker GF
    Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of hERG channel blockers using a decision tree.
    Gepp MM; Hutter MC
    Bioorg Med Chem; 2006 Aug; 14(15):5325-32. PubMed ID: 16616507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
    Zachariae U; Giordanetto F; Leach AG
    J Med Chem; 2009 Jul; 52(14):4266-76. PubMed ID: 19534531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective validation of a comprehensive in silico hERG model and its applications to commercial compound and drug databases.
    Doddareddy MR; Klaasse EC; Shagufta ; Ijzerman AP; Bender A
    ChemMedChem; 2010 May; 5(5):716-29. PubMed ID: 20349498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A composite model for HERG blockade.
    Kramer C; Beck B; Kriegl JM; Clark T
    ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.
    Su BH; Shen MY; Esposito EX; Hopfinger AJ; Tseng YJ
    J Chem Inf Model; 2010 Jul; 50(7):1304-18. PubMed ID: 20565102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refining insights into high-affinity drug binding to the human ether-à-go-go-related gene potassium channel.
    Hancox JC; James AF
    Mol Pharmacol; 2008 Jun; 73(6):1592-5. PubMed ID: 18381562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative structure-activity relationship studies on inhibition of HERG potassium channels.
    Yoshida K; Niwa T
    J Chem Inf Model; 2006; 46(3):1371-8. PubMed ID: 16711756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel structure-based virtual screening model for the hERG channel blockers.
    Du L; Li M; You Q; Xia L
    Biochem Biophys Res Commun; 2007 Apr; 355(4):889-94. PubMed ID: 17331468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards in silico identification of the human ether-a-go-go-related gene channel blockers: discriminative vs. generative classification models.
    Kireeva N; Kuznetsov SL; Bykov AA; Tsivadze AY
    SAR QSAR Environ Res; 2013; 24(2):103-17. PubMed ID: 23152964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HERG K+ channel, the target of anti-arrhythmias drugs].
    Guan FY; Yang SJ
    Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition.
    Yi H; Cao Z; Yin S; Dai C; Wu Y; Li W
    J Proteome Res; 2007 Feb; 6(2):611-20. PubMed ID: 17269718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indexing molecules for their hERG liability.
    Rayan A; Falah M; Raiyn J; Da'adoosh B; Kadan S; Zaid H; Goldblum A
    Eur J Med Chem; 2013 Jul; 65():304-14. PubMed ID: 23727540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.